DUBLIN – After 18 months in stealth mode, Ventus Therapeutics Inc. has emerged with $60 million in series A funding and big ambitions to bring insights from structural biology to bear on two key aspects of innate immunity, inflammasome activation and cGAS-Sting signaling.
DUBLIN – Versant Ventures was one of a handful of investors to profit from Passage Bio Inc.’s recent upsized IPO. The Philadelphia-based gene therapy firm planned to raise $125 million initially but eventually hauled in $216 million by issuing 12 million shares, which it priced at $18 per share on Feb. 27. The IPO price valued Versant’s holding at $89 million. As well as participating in the IPO – the actual amount involved has not been disclosed – it invested $35 million across three private rounds, between September 2018 and August 2019, according to SEC filings.
Century Therapeutics Inc. came out of stealth mode Monday with $250 million in funding commitments from lead investor Bayer AG, founding investor Versant Ventures and strategic partner Fujifilm Holdings Corp. to develop next-generation allogeneic cell therapies for cancer, based on induced pluripotent stem cells (iPSCs).
